Table 2.
Detection of cervical disease using different screening strategies for HR-HPV
| Screening Strategies | Sensitivity (%, 95% CI) | Specificity (%, 95% CI) | PPV (%, 95% CI) | NPV (%, 95% CI) | PLR (%, 95% CI) | NLR (%, 95% CI) | YI (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CIN2+ endpoint | |||||||||||||
| 1 | 86.59 (82.57–90.61) |
95.28 (94.86–95.69) |
33.80 (30.32–37.29) |
99.61 (99.48–99.74) |
18.33 (16.59–20.26) |
0.14 (0.10–0.19) |
81.87 | ||||||
| 2 | 86.59 (82.57–90.61) |
95.28 (94.86–95.69) |
33.80 (30.32–37.29) |
99.61 (99.48–99.74) |
18.33 (16.59–20.26) |
0.14 (0.10–0.19) |
81.87 | ||||||
| 3 | 80.80 (76.15–85.44) |
96.44 (96.07–96.80) |
38.72 (34.74–42.69) |
99.45 (99.30–99.60) |
22.68 (20.16–25.50) |
0.2 (0.16–0.25) |
77.23 | ||||||
| 4 | 89.49 (85.88–93.11) |
90.17 (89.58–90.75) |
20.23 (17.98–22.48) |
99.68 (99.56–99.79) |
9.1 (8.47–9.78) |
0.12 (0.08–0.16) |
79.66 | ||||||
| CIN3+ endpoint | |||||||||||||
| 1 | 88.32 (83.84–92.81) |
94.66 (94.22–95.10) |
24.61 (21.44–27.79) |
99.76 (99.66–99.86) |
16.55 (15.02–18.23) |
0.12 (0.08–0.18) |
82.99 | ||||||
| 2 | 88.32 (83.84–92.81) |
94.66 (94.22–95.10) |
24.61 (21.44–27.79) |
99.76 (99.66–99.86) |
16.55 (15.02–18.23) |
0.12 (0.08–0.18) |
82.99 | ||||||
| 3 | 81.73 (76.33–87.12) |
95.84 (95.45–96.24) |
27.95 (24.29–31.62) |
99.63 (99.5–99.75) |
19.67 (17.53–22.06) |
0.19 (0.14–0.26) |
77.57 | ||||||
| 4 | 89.85 (85.63–94.07) |
89.55 (88.95–90.15) |
14.5 (12.52–16.47) |
99.78 (99.68–99.87) |
8.59 (7.98–9.26) |
0.11 (0.07–0.17) |
79.39 | ||||||
Abbreviations: HR-HPV, high-risk humanpapillomavirus; PPV, positive predictive value; NPV, negative predictive value; PLR, positive likelihood rate; NLR, negative likelihood rate; YI, Youden index; CIN, cervical intraepithelial neoplasia.